Novartis has secured US regulatory approval for Beovu, the company’s latest therapy for neovascular age-related macular degeneration (nAMD), following the drug’s comparable results in head-to-head trials with Eylea. Read more
Perth partnership targets childhood blindness and $1 billion market
The Lions Eye Institute (LEI) has signed a commercial partnership that will combine its antisense gene therapy for a leading cause of childhood blindness with a new Australian-developed drug delivery platform. Read more
Jetrea eye injection receives new PBS listing
A new formulation of the Jetrea intravitreal injection has been listed on Pharmaceutical Benefits Scheme (PBS), replacing the current powder form of the drug. Read more
Latest eye injection proposals draw sharp rebuke from ophthalmology
Controversial plans to dramatically reduce the rebate for intravitreal injections and also allow non-ophthalmologists to perform the procedure have divided Australia’s eyecare sector, with advocacy bodies considering the implications for patients. Read more
Bungling of atropine dispensing prompts second warning
New cases of incorrectly dispensed atropine formulations have prompted calls for eyecare professionals to make annotations to scripts in order to prevent further misunderstandings among pharmacists. Read more
Glaucoma Australia announces new president
Associate professor Simon Skalicky has been announced as Glaucoma Australia’s (GA) new president as the organisation aims to continue its recent success of reaching the country’s glaucoma patients. Read more
Investors take note of Opthea’s potential
Australian biotech company Opthea has reported a solid cash position to further advance clinical trials of its lead drug candidate OPT-302 in FY20, as it moves closer to imposing itself on the macular disease market. Read more
New Australian study results add to Ozurdex?s efficacy
A significant Australian study into the effectiveness of Allergan’s Ozurdex implant as a treatment for Diabetic Macular Oedema (DME) has shown positive results consistent with previously published evidence. Read more
Shares soar as Australian AMD drug outperforms Lucentis
Melbourne-based biotech company Opthea has demonstrated that combination therapy involving its lead drug candidate OPT-302 is superior to standalone Lucentis treatment among neovascular age-related macular degeneration (AMD) patients. Read more
Menicon launches new daily disposable CL
O=MEGA PREVIEW: Menicon Australia will be introducing the newest addition to the Miru family of contact lenses.The company will launch Miru 1day UpSide, the first and only silicone hydrogel daily disposable contact lens incorporated with the manufacturer’s Smart Touch technology. Read more